This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be co…

Gastroesophageal Cancer (GC)Hepatocellular Carcinoma (HCC)Endometrial Cancer+1 more

~Estimated

~$10 – $8,750

Compass TherapeuticsNCT07419841

Phase 1

Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how…

Gastric CancerGastric AdenocarcinomaGastric (Stomach) Cancer+11 more

~Estimated

~$10 – $8,750

BigHat Biosciences, Inc.NCT07529808

Phase 1

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents …

NSCLC AdenocarcinomaGastroesophageal Cancer (GC)Gastric Adenocarcinoma+10 more

~Estimated

~$10 – $8,750

IDEAYA BiosciencesNCT07277413